FINWIRES · TerminalLIVE
FINWIRES
$JNJ

$JNJ

79 stories mentioning JNJUpdated 11d ago

Every FINWIRES story that references JNJ, newest first.

What are analysts saying about JNJ?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on JNJ?

Wire

AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups

AbbVie (ABBV) and other healthcare stocks were rising in recent Thursday trading after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare.According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference.The move could save consumers about $1.1 billion next year, according to estimates obtained by The Associated Press.AbbVie rose 3.1%, Johnson & Johnson (JNJ) was up 2.5%, Bristol-Myers Squibb (BMY) gained 2.8%, and Merck & Co. (MRK) rose 2.1% in the session.The White House didn't immediately reply to' request for comment.Price: $259.00, Change: $+7.94, Percent Change: +3.16%

$ABBV$BMY$JNJ$MRK
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares popped 7%.Johnson & Johnson (JNJ) shares gained 4% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 9% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 8% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ$LLY
Wire

Johnson & Johnson Presents New IMAAVY Data at European Neurology Congress

Johnson & Johnson (JNJ) on Friday presented new data on IMAAVY, nipocalimab-aahu, its treatment for generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness, across 12 abstracts at the European Academy of Neurology 2026 Congress.Data from the Vivacity-MG3 trial showed patients who received IMAAVY alongside standard care early in their disease saw greater symptom reductions versus placebo at week 24 (-4.9 vs. -2.7), with more patients achieving sustained clinical improvement lasting 20 or more weeks, the company said.Patients with less severe disease at baseline showed similar benefit (-4.5 vs. -2.3). Serious adverse events were lower in the IMAAVY arm than placebo (9% vs. 14%), according to the company.IMAAVY is approved by the FDA and European Medicines Agency for adults and patients aged 12 and older with antibody-positive gMG, Johnson & Johnson said.Price: $253.67, Change: $+8.79, Percent Change: +3.59%

$JNJ
Sectors

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Johnson & Johnson (JNJ) shares gained 3.5% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 7% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 9% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 2.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.6%.The iShares Biotechnology ETF (IBB) climbed 1.6%.In corporate news, Johnson & Johnson (JNJ) shares gained 3.5% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.

$JNJ
Wire

CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services on Friday proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price applicability year, transitioning from implementation through annual guidance to codified regulations.The proposal would govern future negotiations and renegotiations for high-cost, single-source drugs covered under Medicare Part D and Part B. CMS said it will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations and future cycles of the program.The rule also proposes a temporary pricing floor for certain small biotech drugs in 2029 and 2030.CMS said it has negotiated prices for 25 high-expenditure drugs during the program's first two years. Maximum fair prices for the first 10 selected drugs took effect Jan. 1, 2026.Price: $236.56, Change: $-4.31, Percent Change: -1.79%

$ABBV$JNJ$LLY$MRK$NVO
Insider Trading

Johnson & Johnson Insider Sold Shares Worth $2,411,500, According to a Recent SEC Filing

Kathryn E Wengel, Executive Vice President, Chief Technical Operations & Risk Officer, on June 11, 2026, sold 10,000 shares in Johnson & Johnson (JNJ) for $2,411,500. Following the Form 4 filing with the SEC, Wengel has control over a total of 114,659 common shares of the company, with 114,288 shares held directly and 371 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/200406/000020040626000127/xslF345X05/wk-form4_1781299408.xml

$JNJ
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) fell 1.8%.In corporate news, Prenetics Global (PRE) shares dropped 8.7% after the company reported a Q1 loss of $1.36 per diluted share, widening from the loss of $0.80 a year earlier.Sanofi (SNY) shares fell 2.3%. The company said it will discontinue a phase 3 trial of riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family. Johnson & Johnson shares rose 0.7%.Pfizer's (PFE) recent share decline has pulled its valuation back toward historical levels, easing some of the concerns raised in its earlier outlook, RBC Capital Markets said. Pfizer's stock fell 0.2%.

$JNJ$PFE$PRE$SNY
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.2%.In corporate news, Prenetics Global (PRE) shares dropped 7% after the company reported a Q1 loss of $1.36 per diluted share, wider than a loss of $0.80 a year earlier.Sanofi (SNY) shares fell 2.3%. The firm said it will discontinue a phase 3 trial of riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family. Johnson & Johnson shares were up 0.8%.

$JNJ$PRE$SNY
Wire

Johnson & Johnson Ordered to Pay $32 Million in California Talc Verdict

Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family.The case was brought on behalf of Maria Lozano, who died in 2024, and was continued by her three children. The family's law firm, Dean Omar Branham Shirley, said Wednesday in a statement that Lozano regularly used Johnson & Johnson's talc-based baby powder beginning in the early 1970s and argued that the product caused her illness.Johnson & Johnson argued that Lozano's asbestos exposure stemmed from other sources, but the jury rejected those theories, the law firm said.Johnson & Johnson didn't immediately reply to a request for comment from.Price: $239.38, Change: $+2.38, Percent Change: +1.00%

$JNJ
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.

$INCY$JNJ$LLY$TNGX
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$INCY$JNJ$LLY
Johnson & Johnson to Acquire Firefly Bio in $1 Billion Deal
US Markets

Johnson & Johnson to Acquire Firefly Bio in $1 Billion Deal

Johnson & Johnson (JNJ) said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.The acquisition will give the company access to Firefly Bio's proprietary Firelink degrader antibody conjugate platform, which is focused on cancers driven by Kirsten rat sarcoma viral oncogene homolog, or KRAS, mutations.The platform is designed to overcome limitations of current treatment limitations by delivering a highly selective protein degrader to tumor cells and avoiding healthy cells, according to Johnson & Johnson."KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years," said John Reed, executive vice president for innovative medicine and research and development at J&J."We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors," Reed said.The acquisition of Firefly Bio is the latest move by Johnson & Johnson to expand its oncology pipeline and advance its aim to develop targeted medicines for the most prevalent and hard-to-treat solid cancer tumors.In December, Johnson & Johnson acquired Halda Therapeutics for $3.05 billion to expand its portfolio of therapies for solid tumors, including prostate cancer, while in March 2024 it acquired Ambrx Biopharma, whose portfolio comprised of products targeting multiple types of cancers, for $2 billion.The deal for Firefly Bio is expected to close later this year, subject to regulatory approvals.Shares of Johnson & Johnson, up about 12% so far this year, were off by about 0.2% in Monday trading.Price: $231.91, Change: $-0.86, Percent Change: -0.37%

$JNJ
Wire

Johnson & Johnson Says Lung Cancer Study on Rybrevant Plus Lazcluze Suggests Potential for More Durable Disease Control

Johnson & Johnson (JNJ) said Friday that updated Phase 1/1b CHRYSALIS-2 data showed Rybrevant plus Lazcluze achieved a median overall survival of 41 months in patients with advanced non-small cell lung cancer with atypical epidermal growth factor receptor mutations.The company said the results add to the evidence showing potential of this combination to deliver durable survival outcomes in both common and atypical EGFR-mutated advanced NSCLC in the first-line setting.The company said the combination previously demonstrated a 57% objective response rate and showed consistent clinical activity across atypical EGFR mutation subgroups.Price: $224.71, Change: $-6.09, Percent Change: -2.64%

$JNJ
Wire

Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning trading Monday, as Wall Street monitored oil prices and US Treasury yields amid the ongoing conflict in the Middle East.In company news, NextEra Energy (NEE) and Dominion Energy (D) said Monday they have entered into a definitive agreement to combine in an all-stock deal. Under the terms of the transaction, Dominion shareholders will receive a fixed exchange ratio of 0.8138 shares of NextEra for each Dominion share they own at the close of the deal, which is expected in the next 12 to 18 months. NextEra shareholders will own about 74.5% of the combined company, while Dominion shareholders will own the remaining 25.5%. NextEra shares were down 5.5% around midday, while Dominion shares were up 9.6%.The US Supreme Court on Monday denied writ of certiorari petitions by six big pharmaceutical companies seeking to challenge the legality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol-Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court. Shares of AstraZeneca, Novartis, Johnson & Johnson and Bristol-Myers were up 1.1%, 0.8%, 0.4% and 0.5%, respectively, while Novo Nordisk was down 1%.Berkshire Hathaway (BRK.A, BRK.B) disclosed Friday in a regulatory filing that it sold all of its stake in UnitedHealth Group (UNH). Separately, a New York state court judge on Monday prohibited prosecutors from using some evidence found in the backpack of Luigi Mangione, who is standing trial for the murder of UnitedHealth Group's UnitedHealthcare CEO Brian Thompson, CNBC reported. UnitedHealth shares were down 1.5%, while Berkshire's class A and class B shares were up 0.2% and 0.1%, respectively.Citigroup (C) and BlackRock's (BLK) HPS Investment Partners are launching a 15 billion euro ($17.48 billion) private capital program to expand access to private financing for corporate and sponsor-owned borrowers in the Europe, the Middle East and Africa region, the companies said Monday. Citigroup shares were down 0.2%, while BlackRock shares were up 0.5%.Price: $88.24, Change: $-5.13, Percent Change: -5.49%

$AZN$BLK$BMY$BRK.A$BRK.B$C$D$JNJ$NEE$NVO$NVS$UNH
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from.Price: $183.25, Change: $+1.67, Percent Change: +0.92%

$AZN$BMY$JNJ$NVO$NVS
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

$AZN$BMY$JNJ$NVO$NVS
Research

Leerink Partners Upgrades Johnson & Johnson to Outperform From Market Perform, Adjusts PT to $265 From $252

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $261, according to analysts polled by FactSet.

$JNJ
Wire

Johnson & Johnson Launches Shockwave C2 Aero Coronary IVL Catheter

Johnson & Johnson (JNJ) said Tuesday it has launched its Shockwave C2 Aero Coronary IVL Catheter, expanding its intravascular lithotripsy portfolio for the treatment of calcified coronary artery disease.The next-generation catheter is designed to enhance deliverability, lesion crossing, and balloon repositioning, the company said.Shockwave C2 Aero is now available in the US and Japan and will be available in Europe and Canada in the coming months, it said.Price: $223.37, Change: $+1.94, Percent Change: +0.87%

$JNJ
Wire

AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says

AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are "overdone," BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers "one of the best" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.Shares of AbbVie were up more than 4% in Thursday trading.Price: $212.77, Change: $+8.88, Percent Change: +4.36%

$ABBV$JNJ

Showing 41-60 of 79

Track with the FINWIRES app suite